Trial Profile
A Single-Arm, Open-Label, Multi-Center Study to Investigate the Objective Response Rate, Safety, and Pharmacokinetics of GSK1120212, a MEK Inhibitor, in Subjects With Metastatic Uveal Melanoma or With Mutation-Positive GNAQ or GNA11 Metastatic Melanoma
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 24 Sep 2023
Price :
$35
*
At a glance
- Drugs Trametinib (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 08 Apr 2011 New trial record